

ADHERENCE TO PROTEIN TYROSINE KINASE INHIBITORS TREATMENT IN CHRONIC MYELOID LEUKAEMIA AND GASTROINTESTINAL STROMAL TUMORS

Diez-Fernández R, Rodríguez-Quesada P, Moreno-García M, Gil-Martín A, Ramón-García J, Molina-García T
Hospital Universitario de Getafe, Madrid, Spain

BACKGROUND

Tyrosine Kinase Inhibitors (TKI) are the standard treatment for Philadelphia chromosome positive chronic myeloid leukaemia (Ph⁺ CML). Imatinib is also indicated on Kit (CD117) positive metastatic malignant gastrointestinal stromal tumors.

The high rates of survival obtained in recent years, have made these diseases to be considered as chronic ones. Thus, adherence to treatment is gaining huge importance.

Many studies have shown that low adherence to treatment with imatinib (< 85-90%), is related to a loss of cytogenetic response in Ph⁺ CML. Current evidence is less for second lines, dasatinib and nilotinib.

PURPOSE

To determine the degree of adherence to treatment with all TKI.

METHODS

One year prospective/retrospective study. All patients on treatment for TKI for at least a month coming to the Pharmacy to collect the medication are included. The study was approved by a research ethics committee and all patients were required to give written informed consent.

Adherence was assessed through two indirect methods:

- Structured interview: adherence was evaluated in a standardized way using the Morisky Medication Adherence Scale.
- Dispensing records: Patients taking less than 90% of the prescribed dose were considered non-adherent.

RESULTS AND DISCUSSION

	Drug	ADH		Days
		DR (%)	MS	
1	Imatinib	85.08	10	1,603
2	Dasatinib	100.00	12	1,247
3	Nilotinib	94.40	13	149
4	Imatinib	96.90	12	1,663
5	Imatinib	99.20	12	1,683
6	Imatinib	99.90	13	1,689
7	Imatinib	99.40	9	1,071
8	Dasatinib	98.30	12	945
9	Imatinib	99.80	13	287
10	Dasatinib	100.00	13	946
11	Dasatinib	90.90	9	1,454
12	Dasatinib	98,00	13	1,470
13	Dasatinib	94.30	12	236
14	Imatinib	97,20	13	1,704
15	Imatinib	98,90	12	1,718

Nineteen patients were having these drugs and 15 accepted to enter the study.

Mean duration of treatment was 1,191 days.

Mean Morisky score (MS) was 11.86 and only three patients were classified as non-adherent. According to the dispensing records (DR), adherence was 96.82 (85.08-100 %) and only one patient showed no adherence (85.08%).

Only one patient showed non adherence with both methods.

CONCLUSIONS

- Patients showed a high level of adherence similar to what has been reported with imatinib.
- High adherence is also seen with new TKI.
- These analyses allow us to identify patients with suboptimal adherence in order to develop educational actions.

Conflict of interest: Nothing to disclose